Overall survival (OS) (A) and cumulative incidence of NRM (B) of allogeneic HCT recipients with TA-TMA (n = 137) vs those with no TA-TMA (n = 238). (A) OS was significantly lower for children with TA-TMA (n = 137; 1-year OS: 75.0% ± 3.8%) vs those with no TA-TMA (n = 238; 1-year OS: 93.2% ± 1.7%) among allogeneic HCT recipients. (B) NRM was significantly higher for patients with TA-TMA (n = 137; 1-year NRM: 21.2% ± 3.6%) vs those with no TA-TMA (n = 238; 1-year NRM: 3.6% ± 1.3%) among allogeneic HCT recipients.